# A Dose-escalation Clinical Study of Intraoperative Photodynamic Therapy of Glioblastoma

Source: https://onco.cc/trials/nct05736406/  
OnCo record `nct05736406` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of Aminolevulinic acid (topical, for photodynamic therapy) in glioma & glioblastoma, run by Hemerion Therapeutics, active and no longer recruiting.

## Summary

A Dose-escalation Clinical Study of Intraoperative Photodynamic Therapy of Glioblastoma is a phase 1/2 interventional study registered as NCT05736406 by Hemerion Therapeutics, with 12 participants enrolled, started 2024-02-20 and due to reach its primary completion in 2026-03-06. Interventions recorded: 5-ALA HCl intraoperative Photodynamic Therapy (PDT) at 200 J/cm^2 and 5-ALA HCl intraoperative Photodynamic Therapy (PDT) at 400 J/cm^2.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT05736406
- Phase: 1/2
- Setting: An Interventional, Multicenter, and International Phase 1/2, Light-dose-escalation Study to Investigate the Safety and Feasibility of Intraoperative Photodynamic Therapy (PDT) With Pentalafen® Drug and Heliance® Solution Device in Male and Female Patients 18 to 75 Years of Age With Grade IV Glioblastoma.
- Sponsor: Hemerion Therapeutics
- Enrolled: 12

## Sources

- ClinicalTrials.gov NCT05736406: https://clinicaltrials.gov/study/NCT05736406

## Connected records

- cancers: [Glioma & glioblastoma](https://onco.cc/cancers/glioblastoma/)
- drugs: [Aminolevulinic acid (topical, for photodynamic therapy)](https://onco.cc/drugs/aminolevulinic-acid/)

---
JSON: https://onco.cc/api/v1/entities/nct05736406.json